CA
AXSM icon

Calton & Associates’s Axsome Therapeutics AXSM Stock Holding History

Calton & Associates’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,810
Closed -$807K – 312
2019
Q4 		$807K Buy
+7,810
New +$315K 0.16% 120

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Calton & Associates's AXSM Position: Q1 2020 in Review

Calton & Associates sold out of Axsome Therapeutics (AXSM) in Q1 2020, closing a stake of 7,810 shares — an estimated $807K sold.

Calton & Associates first reported a position in AXSM in Q4 2019 and held it in 1 quarter. The position peaked at $807K in Q4 2019. 163 funds tracked by Wall St. Rank hold AXSM as of Q1 2020.

  • Calton & Associates reported no remaining Axsome Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Calton & Associates sold 7,810 Axsome Therapeutics shares in Q1 2020, an estimated $807K.
  • Calton & Associates first reported a position in Axsome Therapeutics in Q4 2019 and held it in 1 quarter.
  • Calton & Associates's Axsome Therapeutics position peaked at $807K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2020.

Based on Calton & Associates's 13F filing for Q1 2020, filed 30 Apr 2020.